Skip to main content
. 2023 Mar 15;14(5):e00581. doi: 10.14309/ctg.0000000000000581

Figure 3.

Figure 3.

Kaplan-Meier analyses of OS according to the TACE-A group and TACE-AP group in the crude cohort (a), PSM cohort (b), and sIPTW cohort (c). OS, overall survival; PSM, propensity score matching; sIPTW, stabilized inverse probability of treatment weighting; TACE, transarterial chemoembolization; TACE-A, TACE combined with apatinib; TACE-AP, TACE combined with apatinib and PD-1 inhibitors.